Dapagliflozin OR Farxiga OR SGLT-2 inhibitors OR "Sodium-Glucose Transporter 2 Inhibitors" [Majr] OR "dapagliflozin" [Supplementary Concept] AND Sotagliflozin OR Inpefa OR Dual SGLT 1/2 inhibitors OR "(2S,3R,4R,5S,6R)-2-(4-chloro-3-(4-ethoxybenzyl) phenyl)-6-(methylthio) tetrahydro-2H-pyran-3,4,5-triol" [Supplementary Concept] AND Heart failure or Congestive Heart Failure OR (“Heart Failure/mortality"[Major] OR “Heart Failure/prevention and control"[Major]). This evidence concerns the gene SLC5A2 and heart failure.